{"context":{"query":">>chembl_molecule>>clinical_trials","source_dataset":"chembl_molecule","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":51,"mapped":1},"pagination":{"has_next":false},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"CHEMBL3989958","source":"CHEMBL3989958|IVOSIDENIB","targets":["NCT02989857|Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03173248|Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03839771|A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05615818|Personalized Medicine for Advanced Biliary Cancer Patients|RECRUITING|PHASE3|INTERVENTIONAL","NCT05876754|An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma|RECRUITING|PHASE3|INTERVENTIONAL","NCT06127407|Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen|RECRUITING|PHASE3|INTERVENTIONAL","NCT06465953|Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation|RECRUITING|PHASE3|INTERVENTIONAL","NCT02677922|A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy|ACTIVE_NOT_RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT03013998|Study of Biomarker-Based Treatment of Acute Myeloid Leukemia|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT03155620|Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT03471260|Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT03498521|A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site|COMPLETED|PHASE2|INTERVENTIONAL","NCT03503409|IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT04044209|A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT04056910|Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors|COMPLETED|PHASE2|INTERVENTIONAL","NCT04195555|Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT04278781|AG-120 in People With IDH1 Mutant Chondrosarcoma|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT04493164|CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|RECRUITING|PHASE2|INTERVENTIONAL","NCT04774393|Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT05030441|Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT05401097|IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)|RECRUITING|PHASE2|INTERVENTIONAL","NCT05921760|Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT06081829|A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT06501625|Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT06593548|Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer|NOT_YET_RECRUITING|PHASE2|INTERVENTIONAL","NCT06611839|Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT06707493|Ivosidenib as Post-HSCT Maintenance for AML|RECRUITING|PHASE2|INTERVENTIONAL","NCT07260175|Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma|RECRUITING|PHASE2|INTERVENTIONAL","NCT07282262|An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.|RECRUITING|PHASE2|INTERVENTIONAL","NCT07392242|A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia|RECRUITING|PHASE2|INTERVENTIONAL","NCT02073994|Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation|COMPLETED|PHASE1|INTERVENTIONAL","NCT02074839|Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation|RECRUITING|PHASE1|INTERVENTIONAL","NCT02632708|Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation|ACTIVE_NOT_RECRUITING|PHASE1|INTERVENTIONAL","NCT03071770|Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects|COMPLETED|PHASE1|INTERVENTIONAL","NCT03282513|A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function|COMPLETED|PHASE1|INTERVENTIONAL","NCT03343197|Study of AG-120 and AG-881 in Subjects With Low Grade Glioma|COMPLETED|PHASE1|INTERVENTIONAL","NCT03564821|IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation|COMPLETED|PHASE1|INTERVENTIONAL","NCT04088188|Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma|TERMINATED|PHASE1|INTERVENTIONAL","NCT04176393|A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation|COMPLETED|PHASE1|INTERVENTIONAL","NCT04250051|Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia|ACTIVE_NOT_RECRUITING|PHASE1|INTERVENTIONAL","NCT04655391|Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation|WITHDRAWN|PHASE1|INTERVENTIONAL","NCT04955938|A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms|WITHDRAWN|PHASE1|INTERVENTIONAL","NCT05010772|Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission|RECRUITING|PHASE1|INTERVENTIONAL","NCT05209074|Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma|ACTIVE_NOT_RECRUITING|PHASE1|INTERVENTIONAL","NCT05756777|A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)|RECRUITING|PHASE1|INTERVENTIONAL","NCT06291987|Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation|RECRUITING|PHASE1|INTERVENTIONAL","NCT07006688|A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment|RECRUITING|PHASE1|INTERVENTIONAL","NCT03245424|Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation|APPROVED_FOR_MARKETING|nan|EXPANDED_ACCESS","NCT06181734|Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC|COMPLETED|nan|OBSERVATIONAL","NCT06265545|Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia|RECRUITING|nan|INTERVENTIONAL","NCT07131059|MRD-positive AML Clinical Study|RECRUITING|nan|INTERVENTIONAL"]}]}